The Company And Summary Of Significant Accounting Policies (Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income Per Share Computations) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended														12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2011		Sep. 30, 2011		Jun. 30, 2011		Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
The Company And Summary Of Significant Accounting Policies [Abstract]
Net income	$ 1,888	$ (13,161)	[1],[2]	$ 11,228	[3]	$ 9,665	[4]	$ 11,550	[5],[6]	$ 10,832	[7]	$ 1,891	[8],[9]	$ 3,849	$ 9,620	$ 28,122	$ 21,081
Weighted-average shares outstanding used to compute basic net income per share															56,637	55,110	47,624
Effect of dilutive securities															1,846	2,277	1,790
Weighted-average shares outstanding used to compute diluted net income per share															58,483	57,387	49,414
Basic net income per share	$ 0.03	$ (0.23)	[1]	$ 0.20	[3]	$ 0.17	[4]	$ 0.20	[5],[6]	$ 0.19	[7]	$ 0.03	[8],[9]	$ 0.08	$ 0.17	$ 0.51	$ 0.44
Diluted net income per share	$ 0.03	$ (0.23)	[1]	$ 0.19	[3]	$ 0.16	[4]	$ 0.19	[5],[6]	$ 0.18	[7]	$ 0.03	[8],[9]	$ 0.08	$ 0.16	$ 0.49	$ 0.43

[1] For the three months ended September 30, 2012, the restatement revisions had an impact of increasing revenues, decreasing cost of product sales, and increasing net income by $7,000, $1,000 and $0.4 million, respectively, and increasing basic and diluted earnings per share by $0.01.

[2] During the three months ended September 30, 2012, the Company identified an impairment indicator with respect to its intangible assets related to its promotion and distribution contract rights and recorded losses of approximately $42.7 million to recognize the full impairment and recorded a benefit for income tax of approximately $6.8 million due to the impairment of intangible assets, which resulted in a reversal of deferred tax liabilities. This was partially offset by the impact of recognizing a full valuation allowance on any remaining NovaMed deferred tax assets. In addition, for the same period, the Company recorded a non-cash gain of $12.8 million, primarily related to the decrease in estimated probability of achieving targets relating to NovaMed’s product distributor agreements, including the renewal of the agreement with Sanofi for a five-year term.

[3] For the three months ended June 30, 2012, the restatement revisions had an impact of increasing revenues, cost of product sales, and net income by $1.1 million, $0.4 million and $0.6 million, respectively, and increasing basic and diluted earnings per share by $0.01.

[4] For the three months ended March, 2012, the restatement revisions had an impact of increasing revenues, cost of product sales, and net income by $1.9 million, $0.6 million and $1.0 million, respectively, and increasing basic and diluted earnings per share by $0.02 and $0.01, respectively.

[5] For the three months ended December 31, 2011, the restatement revisions had an impact of decreasing revenues, cost of product sales, and net income by $1.8 million, $0.9 million, and $0.9 million, respectively, and decreasing basic and diluted earnings per share by $0.01 and $0.02, respectively.

[6] Changes to the selected quarterly financial data for the three months ended December 31, 2011 mainly related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.

[7] For the three months ended September 30, 2011, the restatement revisions had an impact of increasing revenues, cost of product sales, and net income by $1.9 million, $1.2 million and $0.6 million, respectively, and increasing basic and diluted earnings per share by $0.01.

[8] For the three months ended June 30, 2011, the restatement revisions had an impact of decreasing revenues, cost of product sales, and net income by $1.2 million, $1.0 million and $0.1 million, respectively, and decreasing diluted earnings per share by $0.01.

[9] On April 18, 2011, SciClone acquired NovaMed. Commencing April 18, 2011, the Company’s financial statements include the assets, liabilities, operating results and cash flows of NovaMed.